Short-term effects of rituximab on flow-mediated dilatation may be mediated by intravenous glucocorticoids: comment on the article by Gonzalez-Juanatey et al.
Sandoo
Aamer
A
Toms
Tracey
T
Zanten
Jet Veldhuijzen van
JV
Carroll
Douglas
D
Kitas
George
G
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000503:physiopathology; D001798:Blood Proteins / Q000187:drug effects; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007262:Infusions, Intravenous; D008055:Lipids / Q000097:blood; D008775:Methylprednisolone / Q000008:administration & dosage / Q000494:pharmacology*; D012039:Regional Blood Flow / Q000187:drug effects / Q000502:physiology; D000069283:Rituximab; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D001798:Blood Proteins; D005938:Glucocorticoids; D008055:Lipids; D000069283:Rituximab; D008775:Methylprednisolone